Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 4Phase 3 1

Status

Withdrawn 2Terminated 2Recruiting 2Completed 1

Sponsor Class

OTHER 7INDUSTRY 3NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

CNS 3Gynecologic 2NET 1Endocrine 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Meningioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × OTHER × TIC10 compound × Clear all
NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn
CNS

Meningioma

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting
360 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
62 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03099499 2024-12-24

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Fox Chase Cancer Center

Phase 2 Terminated
19 enrolled
Gynecologic

Endometrial Neoplasms

NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT04629209 2023-11-24

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
CNS

Glioblastoma

NCT03733119 2022-03-10

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

University of Wisconsin, Madison

Phase 2 Terminated
4 enrolled 10 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡